SignalXSignalX

DNTH Dianthus Therapeutics, Inc. /DE/

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Dianthus Therapeutics, Inc. /DE/ Overview

Dianthus Therapeutics, Inc. /DE/ (DNTH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • No new or updated risks disclosed this quarter compared to 10-K ended December 31, 2024
  • • Continued risk of material harm to business and stock price decline from events described in 10-K risks
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$396,000

▲ +105.2% QoQ

Net Income

-$37M

▼ -46.0% YoY▼ -16.2% QoQ

Operating Margin

-10173.7%

▲ +792315bp QoQ

Net Margin

-9284.1%

▲ +710399bp QoQ

ROE

-6.7%

Total Assets

$577M

EPS (Diluted)

$-0.97

▼ -31.1% YoY▼ -9.0% QoQ

Operating Cash Flow

-$31M

▼ -43.7% YoY▼ -27.9% QoQ

Source: XBRL data from Dianthus Therapeutics, Inc. /DE/ Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Dianthus Therapeutics, Inc. /DE/

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.